IntroductionAgrin is an extracellular matrix protein belonging to the heterogeneous family of heparan sulfate proteoglycans (HSPGs), which are key molecules involved in skeletal development, hematopoiesis, and inflammation, 1,2 as well as in leukocyte adhesion and motility. 3 Agrin has been extensively studied in the context of the neuromuscular junction (NMJ), where the protein exerts a key role as regulator of postsynaptic differentiation. 4 However, although agrin is broadly expressed during development, 5,6 little is known approximately its role at sites other than the NMJ. In the context of leukocytes, a previous study suggested that agrin may be a regulator of the T-cell immunologic synapse, where it may act as a costimulatory molecule by recruiting lipid rafts. 7 More recently it was reported by our group that agrin deficiency on bone marrow (BM) stroma leads to a defect in CD34 ϩ CD135 Ϫ LSK cell differentiation resulting in reduced cell numbers of all hematopoietic cell lineages. 8 Our studies, as well as previous ones, indicated that the agrin receptor in hematopoietic cells is ␣-dystroglycan (␣-DG), a broadly expressed cell-surface receptor with high affinity for extracellular matrix (ECM) proteins. 9 Although both agrin and ␣-DG are expressed in mature hematopoietic cells, 7,10 the in vivo functional significance of their expression is still unclear. The aim of this study was to analyze the involvement of agrin in leukocyte biology. By using mice that are null for agrin, 11 we demonstrate that agrin is a critical player in the development and function of monocytes and macrophages.
Methods
MiceAgrin-deficient mice have been described elsewhere. 11 Musk-LAgrn Ϫ/ϩ mice (on C57BL/6 background) were bred at the animal facility of the Humanitas Clinical Institute. Mutant and control mice were genotyped by polymerase chain reaction (PCR) of tail DNA as already described. 11 Congenic B6(CD45.1) mice, purchased from Jackson ImmunoResearch Laboratories, were maintained in the Charles River animal facility and used as recipients of BM transplantation experiments. Procedures involving animals and their care conformed to institutional guidelines in compliance with national (4D.L. N.116, G.U., suppl. 40, 18-2-1992) and international (EEC Council Directive 86/609, OJ L 358,1,12-12-1987; National Institutes of Health Guide for the Care and Use of Laboratory Animals) law and policies. All efforts were made to minimize the number of animals used and their suffering.
BM transfer assaysFor BM transfer experiment 1 ϫ 10 6 BM cells from P5 Musk-LAgrn Ϫ/Ϫ or control mice were transferred into 8-to 12-week-old B6(CD45.1) recipients, that were placed under antibiotic treatment 1 week before and 2 weeks after irradiation (950 cGy). Mice were killed and analyzed 9 weeks after transfer; a second BM transfer was performed as the first and analyzed 9 weeks later.
HistologyTissues were fixed in 4% (weight/volume) formalin, embedded in paraffin, sectioned, and stained with H&E.
Immunohistochemistry and immunofluorescenceSections (5...